Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Af­ter cre­at­ing an­ti­body mak­ers Apogee and Spyre, Paragon Ther­a­peu­tics is back with an­oth­er in­flam­ma­to­ry and im­mune dis­ease biotech, and the start­up is im­me­di­ate­ly go­ing to the pub­lic mar­kets.

Waltham, MA-based bi­o­log­ics mak­er Oru­ka Ther­a­peu­tics, fo­cused on chron­ic skin dis­eases like plaque pso­ri­a­sis, has inked a re­verse merg­er agree­ment with a lit­tle-known Col­orado biotech that had at­tempt­ed to break in­to the dif­fi­cult car­dio­vas­cu­lar field of atri­al fib­ril­la­tion, or ir­reg­u­lar and rapid heart rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER